Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Autorenporträt
Daniel Gibbs is a retired general neurologist with mild Alzheimer's dementia. He has written previously about his experiences as seen from two points of view, doctor and patient, in A Tattoo on my Brain: A Neurologist's Personal Battle against Alzheimer's Disease, Cambridge University Press, 2021 and 2023 (revised edition).
Inhaltsangabe
1. Physician heal thyself 2. Evaluating new advances in Alzheimer's research - separating hype from fact 3. Alzheimer's dementia or Alzheimer's disease - what's the difference and why should we care? 4. The first patient with Alzheimer's disease 5. Kidnapped in Kinshasa 6. Smell, disgust and Alzheimer's 7. Apolipoprotein-4 (APOE-4): bad for the brain and bad for the heart 8. Lost in the fog of Alzheimer's 9. My father's 'stuff' 10. Face blindness during a pandemic 11. Biomarkers for Alzheimer's disease 12. Olfactory impairment in Covid-19 and Alzheimer's 13. Alzheimer's disease and work 14. Crossword controversies 15. Can loneliness increase risk for dementia? 16. Excessive laxative use and dementia 17. Dog dementia (canine cognitive dysfunction) 18. The possible role of brain inflammation in Alzheimer's disease may be more significant in APOE-4 carriers 19. Surprisingly good news about the acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) 20. More about the importance of exercise 21. Rolling on the river 22. The MIND Diet revisited 23. My photographs, then and now 24. Does cataract surgery really decrease the risk of dementia? 25. Hearing loss, aphasia and dementia 26. To sleep, perchance to dream 27. The amyloid hypothesis is not dead, but it may be gasping for breath 28. Could Lecanemab offer a ray of hope? 29. A fatal case of multiple brain hemorrhages associated with Lecanemab 30. Cerebral amyloid angiopathy (CAA) - should it be a contraindication for drugs like Lecanemab? 31. Hitting the sweet spot in the spectrum of Alzheimer's disease for future trials of anti-amyloid medications 32. Disappointing results of two human trials of monoclonal antibodies in Parkinson's disease 33. Repurposing old drugs for Alzheimer's treatment 34. Writing while impaired 35. Spreading the word 36. Saying goodbye to Lizzy G 37. Amyloid and tau PET scans of my brain 38. Running on a field of dreams 39. Living in the moment.
1. Physician heal thyself 2. Evaluating new advances in Alzheimer's research - separating hype from fact 3. Alzheimer's dementia or Alzheimer's disease - what's the difference and why should we care? 4. The first patient with Alzheimer's disease 5. Kidnapped in Kinshasa 6. Smell, disgust and Alzheimer's 7. Apolipoprotein-4 (APOE-4): bad for the brain and bad for the heart 8. Lost in the fog of Alzheimer's 9. My father's 'stuff' 10. Face blindness during a pandemic 11. Biomarkers for Alzheimer's disease 12. Olfactory impairment in Covid-19 and Alzheimer's 13. Alzheimer's disease and work 14. Crossword controversies 15. Can loneliness increase risk for dementia? 16. Excessive laxative use and dementia 17. Dog dementia (canine cognitive dysfunction) 18. The possible role of brain inflammation in Alzheimer's disease may be more significant in APOE-4 carriers 19. Surprisingly good news about the acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) 20. More about the importance of exercise 21. Rolling on the river 22. The MIND Diet revisited 23. My photographs, then and now 24. Does cataract surgery really decrease the risk of dementia? 25. Hearing loss, aphasia and dementia 26. To sleep, perchance to dream 27. The amyloid hypothesis is not dead, but it may be gasping for breath 28. Could Lecanemab offer a ray of hope? 29. A fatal case of multiple brain hemorrhages associated with Lecanemab 30. Cerebral amyloid angiopathy (CAA) - should it be a contraindication for drugs like Lecanemab? 31. Hitting the sweet spot in the spectrum of Alzheimer's disease for future trials of anti-amyloid medications 32. Disappointing results of two human trials of monoclonal antibodies in Parkinson's disease 33. Repurposing old drugs for Alzheimer's treatment 34. Writing while impaired 35. Spreading the word 36. Saying goodbye to Lizzy G 37. Amyloid and tau PET scans of my brain 38. Running on a field of dreams 39. Living in the moment.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
